Tags

Type your tag names separated by a space and hit enter

Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy.
Ann Pharmacother. 2000 Apr; 34(4):479-82.AP

Abstract

OBJECTIVE

To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette-Guérin (BCG) and to review the incidence of this adverse effect.

DATA SOURCES

Information about the patient was obtained from the medical chart. A MEDLINE search of English-language literature (from January 1976 to April 1999) was conducted.

STUDY SELECTION

All case reports of BCG-related epididymo-orchitis were evaluated. Review articles describing complications of BCG therapy for bladder cancer and the prevention and treatment of these complications were reviewed.

DATA EXTRACTION

Studies were evaluated for reports of BCG-related epididymo-orchitis and its treatment.

DATA SYNTHESIS

Our case report is compared with others reported in the literature. The incidence of BCG-associated epididymoorchitis is rare.

CONCLUSIONS

Epididymo-orchitis should be considered as a late complication of BCG therapy for bladder cancer. Proper patient selection may help decrease the risk of complications from BCG therapy.

Links

Publisher Full Text

Authors+Show Affiliations

Menke JJ
South Dakota State University, Brookings, USA. Jennifer.menke@med.va.gov
Heins JR
No affiliation info available

MeSH

Adjuvants, ImmunologicAdministration, IntravesicalAgedBCG VaccineCarcinoma, Transitional CellEpididymitisHumansIncidenceMaleOrchitisUrinary Bladder Neoplasms

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng

PubMed ID

10772435

Citation

Menke, J J., and J R. Heins. "Epididymo-orchitis Following Intravesical Bacillus Calmette-Guérin Therapy." The Annals of Pharmacotherapy, vol. 34, no. 4, 2000, pp. 479-82.
Menke JJ, Heins JR. Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy. Ann Pharmacother. 2000;34(4):479-82.
Menke, J. J., & Heins, J. R. (2000). Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy. The Annals of Pharmacotherapy, 34(4), 479-82.
Menke JJ, Heins JR. Epididymo-orchitis Following Intravesical Bacillus Calmette-Guérin Therapy. Ann Pharmacother. 2000;34(4):479-82. PubMed PMID: 10772435.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy. AU - Menke,J J, AU - Heins,J R, PY - 2000/4/20/pubmed PY - 2000/7/6/medline PY - 2000/4/20/entrez SP - 479 EP - 82 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 34 IS - 4 N2 - OBJECTIVE: To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette-Guérin (BCG) and to review the incidence of this adverse effect. DATA SOURCES: Information about the patient was obtained from the medical chart. A MEDLINE search of English-language literature (from January 1976 to April 1999) was conducted. STUDY SELECTION: All case reports of BCG-related epididymo-orchitis were evaluated. Review articles describing complications of BCG therapy for bladder cancer and the prevention and treatment of these complications were reviewed. DATA EXTRACTION: Studies were evaluated for reports of BCG-related epididymo-orchitis and its treatment. DATA SYNTHESIS: Our case report is compared with others reported in the literature. The incidence of BCG-associated epididymoorchitis is rare. CONCLUSIONS: Epididymo-orchitis should be considered as a late complication of BCG therapy for bladder cancer. Proper patient selection may help decrease the risk of complications from BCG therapy. SN - 1060-0280 UR - https://www.unboundmedicine.com/medline/citation/10772435/Epididymo_orchitis_following_intravesical_bacillus_Calmette_Guérin_therapy_ L2 - https://journals.sagepub.com/doi/10.1345/aph.19212?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -